Open · RFA-DA-26-034 · CFDA 93.233;93.279;93.837;93.838;93.839;93.840;93.855 · Discretionary

Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed)

Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.

up to $300K
Award range
Open
Status
477d
Days left
-
Expected awards

The verdict

Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed) is an open discretionary opportunity from National Institutes of Health, offering Up to $300,000. Applications close in 477 days.

up to $300K
award range
Open
477 days left
93.233;93.279;93.837;93.838;93.839;93.840;93.855
CFDA program

Opportunity snapshot. This Grants.gov announcement - Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed) - is cataloged under number RFA-DA-26-034 and tied to CFDA assistance listing 93.233;93.279;93.837;93.838;93.839;93.840;93.855, posted by National Institutes of Health. Grants.gov currently shows the opportunity as open, first posted on November 20, 2024 and last updated on August 12, 2025. The funding category is Discretionary, delivered as a grant.

Award economics. The award range on file is Up to $300,000. The agency has projected $300,000 in total estimated funding for this announcement. Cost sharing is not required, so applicants do not need to commit matching funds to be competitive on this opportunity. Federal award ranges are often upper bounds; actual allocations reflect program appropriations, the strength of the applicant pool, and the evaluation committee's scoring.

Deadline and action path. Applications close on November 18, 2027 - roughly 477 days from today. Every Grants.gov submission requires an active SAM.gov registration and a Unique Entity ID. Review the Eligibility section below carefully, federal eligibility categories (nonprofit, state or local government, tribal, individual, educational institution, small business) have distinct registration and reporting requirements. Pre-application outreach to the listed agency contact is permitted and often welcomed, it helps clarify scope and scoring priorities. Before acting on the deadline or award figures above, verify them directly on the official Grants.gov listing, amendments can change dates and amounts after this page was last refreshed.

Award Range

Up to $300,000

Close Date

November 18, 2027

Posted

November 20, 2024

Est. Total Funding

$300,000

Instrument

Grant

Description

This notice of funding opportunity (NOFO) will support research towards understanding and mitigating the deleterious effects of acute exposure to Ultra-Potent Synthetic (UPS) opioids (e.g., fentanyl, carfentanil, nitazenes) and their combinations (fentanyl and xylazine). This NOFO will also support research on the persistent and/or delayed pathophysiological effects after acute exposure to such agents.

Eligibility

Grants.gov lists this opportunity under eligibility category codes 00, 01, 02, 04, 05, 06, 07, 08, 11, 12, 13, 20, 22, 23, 25. These codes correspond to applicant types (state/local government, tribal organization, nonprofit, educational institution, individual, small business, etc.) defined in Grants.gov's own eligibility reference. See the current Grants.gov eligibility categories or check the official listing below for this opportunity's exact eligibility statement.

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Agency Contact

NIH Grants Information grantsinfo@nih.gov

Key Dates

Posted November 20, 2024
Close Date November 18, 2027
Archive Date December 24, 2027
Last Updated August 12, 2025

Frequently Asked Questions

What is this grant opportunity?
This is a federal funding opportunity titled "Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed)", offered by National Institutes of Health. It is associated with CFDA program 93.233;93.279;93.837;93.838;93.839;93.840;93.855. This notice of funding opportunity (NOFO) will support research towards understanding and mitigating the deleterious effects of acute exposure to Ultra-Potent Synthetic (UPS) opioids (e.g., fentanyl, ...
Is this opportunity still open?
Yes, this opportunity is currently open for applications. The closing date is November 18, 2027.
How much funding is available?
The award range for this opportunity is Up to $300,000. Total estimated funding: $300,000.
How do I apply?
Applications for federal grant opportunities are typically submitted through Grants.gov. Visit the official listing at grants.gov for application instructions, required documents, and submission deadlines.

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Data sourced from the SAM.gov Assistance Listings and Grants.gov. See our methodology for details. Retrieved and formatted by PlainGrants